Patient safety during anesthesia in Ukraine: national audit results.

BACKGROUND: Although anesthesiologists are one of the leaders in patient safety, anesthesia in low and low-middle income countries still need improvement in safety mesures with evidence-based practice application. The study aim was to audit the safety principles implementation in the Ukrainian anesthesiologist`s practice. METHODS: The study was held in March 2021-Februrary 2022 by filling out an online questionnarie. The link to the survey was distributed through Ukrainian Anesthesiologists Association (UAA) members emails and also published on UAA webpage and facebook page. The email was sent to 1000 UAA members. RESULTS: Summary 210 respondents took part in the study. Among the respondents, 79.1% of respondents are aware of the Helsinki Declaration on Patient Safety in Anesthesiology, but only 40,3% declared that the principles of this Declaration had been implemented in their medical institutions. Even though most of the respondents declared that the quality of the work has improved with the application of the Helsinki Declaration, 16% stated, that there is no positive impact. Most of the medical institutions include mandatory perioperative monitoring, while 17% of hospitals have no access to pulse oximetry for all patients in the operating room and intensive care unit. Concerning using clinical protocols, the one on the treatment of massive bleeding is used in 60.3% of cases, on infection control in 60.5%. In relation to checklists, 28.2% of respondents have never heard about the WHO Safe Surgery checklist. Checklists for equipment inspection are used in only 27.8% of medical institutions. 72.8% hospitals keep records of anaesthesia complications. CONCLUSION: The study showed that significant positive steps are being taken to improve patient safety in Ukraine, where most hospitals comply with the minimum standarts of monitoring during anesthesia. Although there are many challenges for improvement, more hospitals need to implement WHO Safe Surgery and equipment checklists, protocols etc. These areas are a priority for further development in Ukraine. TRIAL REGISTRATION: Clinicaltrials.gov NCT05175976 on 04/01/2022.

Knowledge and Attitudes about Helsinki Declaration on Patient Safety among Anaesthesiologists in Turkey: A Questionnaire Study.

OBJECTIVE: The Helsinki Declaration on Patient Safety in Anaesthesiology is an important document for anaesthesiologists. This study aimed to evaluate the knowledge and experiences of anaesthesiologists in Turkey on the "Helsinki Declaration on Patient Safety." METHODS: After the ethics committee approval and participants' consent, electronic questionnaires were sent to anesthetists working in Turkey. The questionnaire included 48 questions. RESULTS: The mean age of the participants was 44.28±8.01 years, and 52.1% were women (n=142). The mean time spent in the field of anesthesiology was 12.83±7.76 years. The percentage of participants working in private hospitals was 13.4%. A total of 58.5% of the participants were educated on patient safety out of whom 57% said that their knowledge was sufficient, 37.3% said that it was limited, and 5.6% felt that it was insufficient. The knowledge of participants about the Helsinki Declaration was sufficient in 31.7%, limited in 39.4%, insufficient in 9.2%, and 19.7% had no knowledge. A total of 27% of participants believed that implementation of the Helsinki Declaration improved patient safety. It has been stated that the minimum patient monitoring standards recommended by the European Board of Anaesthesiology has been complied in operating rooms and recovery units (90.8% and 78.2%, respectively). CONCLUSION: The findings of this survey might guide not only the individual anesthetists but also hospital administrators to develop strategies to improve patient safety and thus quality of care in the light of the recommendations listed in the Helsinki Declaration.

Anti-doping research and the Helsinki Declaration: (mis)match?

The fight against doping in sport is internationally coordinated by the World Anti-Doping Agency (WADA). Through its World Anti-Doping Code, WADA aims to harmonize anti-doping policies, rules and regulations. One key reference document bound to the Code is the International Standard for Laboratories (ISL), which mainly specifies the criteria that must be met for laboratory accreditation, as well as standards to adopt for the production of valid test results and evidentiary data. Within the ISL, the Code of Ethics refers to the Helsinki Declaration as a guiding framework for anti-doping research. However, inasmuch as anti-doping research structurally differs from human subject research as considered by the Helsinki Declaration, the applicability of the latter to anti-doping research can be called into question. In this work, we discuss how key principles of the Helsinki Declaration apply to anti-doping research and highlight frictions, incompatibilities and misalignments. Furthermore, we indicate possible solutions for operationalizing the Helsinki principles within the context of anti-doping research.

An overview of primary registries of WHO's international clinical trial registry platform.

INTRODUCTION: WHO's International Clinical Trials Registry Platform (ICTRP) has 17 primary registries that collect the information on the minimum set of items of trial information that appear in the register and these registries are also endorsed by the International Committee of Medical Journal Editors. OBJECTIVE: The objective of this study is to describe the profile of all the primary registries including Clinical Trial Registry­India (CTRI), through features such as magnitude, domain of registration, flagging, audit trail, language, mandatory requirements, and result disclosure. METHODOLOGY: The profiling of all registries was based on countries and zones, year of establishment, registrant, flagging, conflict of interest, language, documents, result disclosure, type of study, mode of registration, mandate of registration, quality check method, individual patient data statement and translation of content facility. The mode of search used was online which included advanced search, basic search and also from the audio/video manual on their website. RESULTS: There are 17 primary registries of ICTRP, the first one International Standard Randomised Controlled Trial Number (ISRCTN) of England being initiated in year 2000 and the most recent being Lebanese registry, in September 2019. The trials registered with these registries range from 301 in Cuba to 53972 in European union's EU Clinical Trials Register. The primary registries in WHO registry network are diverse in functionalities and practices. The characteristics of online registers vary in content and features and to achieve coordinated level of data quality, across all the different registries and to keep a balance in standards of the data collected and validation of that data, the registries are adhering to the minimum data set items laid down by ICTRP. CONCLUSION: The very process of registering the clinical studies helps in promoting the research methods and also raising the standards of research, especially among young researchers. It also helps in reducing the duplicity of research.

A Wake-Up Call: We Need Phage Therapy Now.

The rise of multidrug-resistant bacteria has resulted in an increased interest in phage therapy, which historically preceded antibiotic treatment against bacterial infections. To date, there have been no reports of serious adverse events caused by phages. They have been successfully used to cure human diseases in Eastern Europe for many decades. More recently, clinical trials and case reports for a variety of indications have shown promising results. However, major hurdles to the introduction of phage therapy in the Western world are the regulatory and legal frameworks. Present regulations may take a decade or longer to be fulfilled. It is of urgent need to speed up the availability of phage therapy.

Surveying opinions of 149 registrants to the Research Registry: Awareness of and attitudes towards research registration.

BACKGROUND: Research registration is an important ethical principle in the Declaration of Helsinki, however, progress to increase registration has been slow. Understanding the attitudes of users towards registries may provide insights into increase research registration. In this survey-based study, we sought to gain insight from users of a single global research registry, the Research Registry® (www.researchregistry.com). METHODS: A Google Forms survey was created and emailed to all users of the Research Registry® (n = 1432). Multiple choice and free-text answers were analyzed using descriptive statistics and thematic analysis respectively. RESULTS: From 925 contactable registrations, 149 (16.1%) completed the survey. The most commonly registered study type was retrospective cohort (32.2%). 23 registrations (15.4%) were made during the planning or conception of the study, whereas 67 (45.0%) registered at the time of journal submission, or during the peer review process. Of those that declared whether they had performed unregistered research or not, 51 (45.5%) participants had previously performed unregistered research. Registrants were most commonly made aware of the Research Registry® through submission to the International Journal of Surgery (IJS) family of journals (n = 57, 47.5%). Survey participants identified the most important features of registration to be its convenience, including the ease, time and cost of registration. Thematic analysis revealed the most common motive for registration to be as a mandatory requirement of journal submission, and that registration can be improved by simplification of the registration process. CONCLUSION: Registries must focus on engaging their network of users to ensure that research registration is a dynamic process. They need to adopt a user-centered and agile approach to their development, with a strong focus on "customer service". Moreover, by working in partnership with journals, it is possible to improve compliance with registration.

The First 500 Registrations to the Research Registry®: Advancing Registration of Under-Registered Study Types.

INTRODUCTION: The Declaration of Helsinki 2013 encourages the registration of all research studies involving human participants. However, emphasis has been placed on prospective clinical trials, and it is estimated that only 10% of observational studies are registered. In response, Research Registry® was launched in February 2015; a retrospectively curated registry that is free and easy to use. Research Registry® enables prospective or retrospective registration of studies, including those study types that cannot be registered on existing registries. In this study, we describe the first 500 registrations on Research Registry®. METHODS: Since the launch of Research Registry® in February 2015, data of registrations have been collected, including type of studies registered, country of origin, and data curation activity. Inappropriate registrations, such as duplicates, were identified by the data curation process. These were removed from the database or modified as required. A quality score was assigned for each registration, based on Sir Austin Bradford Hill's criteria on what research studies should convey. Changes in quality scores over time were assessed. RESULTS: A total of 500 studies were registered on Research Registry® from February 2015 to October 2015, with a total of 1.7 million patients enrolled. The most common study types were retrospective cohort studies (37.2%), case series (14.8%), and first-in-man case reports (10.4%). Registrations were received from 57 different countries; the most submissions were received from Turkey, followed by China and the United Kingdom. Retrospective data curation identified 80 studies that were initially registered as the incorrect study type, and were subsequently correct. The Kruskal-Wallis test identified a significant improvement in quality scores for registrations from February 2015 to October 2015 (p < 0.0001). CONCLUSIONS: Since its conception in February 2015, Research Registry® has established itself as a new registry that is free, easy to use, and enables the registration of various study types, including observational studies and first-in-man case reports. Going forward, our plan is to continue developing Research Registry® in line with user feedback and usability studies. We plan to further promote Research Registry® to advance the cause of registration of research, to increase compliance with the Declaration of Helsinki 2013.

Approaches to Increasing Ethical Compliance in China with Drug Trial Standards of Practice.

Zeng et al.'s Ethics Review highlights some of the challenges associated with clinical research in China. They found that only a minority of published clinical trials of anti-dementia drugs reported that they fulfilled the basic ethical principles as outlined in the Declaration of Helsinki. With recent reports of scientific misconduct from China, there is an urgent need to find approaches to compel researchers to adhere to ethical research practices. This problem does not call for a simple solution, but if forces are joined with governmental regulations, education in ethics issues for medical researchers, and strong reinforcement by Chinese journal editors not to publish studies with these flaws, then research ethics and publication standards will probably improve. Other solutions to foster ethical practice of drug trials are discussed including Chinese initiatives directed at managing conflict of interest from the pharmaceutical industry and educating clinical researchers.

Declaración de Helsinki: cambios y exégesis / Helsinki Declaration: changes and interpretation

La Declaración de Helsinki es muy citada de en el ámbito de las ciencias médicas y de la salud. En Cuba se utiliza para valorar los aspectos éticos de las investigaciones, sin embargo es escasa la literatura dedicada a la valoración crítica de la misma. Referir sus versiones presupone conocer su devenir histórico para interpretar sus aciertos y limitaciones. La intención del estudio es contribuir a actualizar los conocimientos de los profesionales de la salud sobre la Declaración de Helsinki. Se realizó revisión de la literatura publicada entre 2008 y 2014 (agosto) en las bases de datos bibliográficos Cumed, Lilacs, SciELO PubMed, MedLine, Clinical Key, Cochrane y el motor de búsqueda Google utilizando vocabulario controlado con los siguientes descriptores: Declaración de Helsinki, placebo, ensayo clínico, ética y bioética. Los temas más polémicos fueron: uso del placebo, doble estándar en las investigaciones clínicas y garantía de continuidad de tratamiento a los pacientes participantes. Se destacaron méritos en la versión de 2013 tales como la insistencia para aumentar la transparencia en la investigación, su nuevo diseño estructural y la consideración de la competencia ética como un requisito para los investigadores. Los comentarios sobre la Declaración de Helsinki oscilan desde el elogio hasta la sugerencia de su desaparición o sustitución. La polémica sobre la misma es considerada necesaria por algunos autores pero también estéril por otros. Los problemas más álgidos tratados en las últimas versiones emanan del enfrentamiento entre los intereses de la industria farmacéutica y los derechos de los participantes en las investigaciones(AU)

In the fields of medical and health sciences, the Helsinki Declaration is quoted very often. The Helsinki Declaration is used to evaluate the ethical aspects of research studies; however, literature devoted to critical assessment of those studies is scanty. Making reference to the declaration versions presupposes the knowledge about its historical development in order to construe its good things and limitations. The intention of this study is to help to update the health professionals' knowledge about the Helsinki Declaration. A literature review published between 2008 and August 2014 was made and collected on the following databases: Cumed, Lilacs, SciELO PubMed, MedLine, Clinical Key, Cochrane and Google, using controlled vocabulary with the f subject headings Helsinki Declaration, placebo, clinical trial, ethics and bioethics. The most controversial topics were the use of placebo, application of the double standard possition in clinical research, and guaranteed continuous treatment for the participating patients. The following 2013 version's merits were highlighted: insistence on the research transparency its new structural design, and the concern for ethical competence as a requirement for researchers. Comments about the Helsinki Declaration range from praise to disappearance or replacement suggestions. Some authors deem the controversy necessary but others think it is a wasteful argument. The hottest problems in the most recent versions come from the confrontation between the pharmaceutical industry interests and the rights of participants in research studies(AU)

[Wisdom of the World Medical Association (to one forgotten anniversary)]. / Moudrost Svetové lékarské asociace (k pozapomenutému výrocí).

BACKGROUND: The idea to found an international medical organization was born in July 1945 at the informal conference of doctors from several countries which was held in London. This date represents the very beginning of The World Medical Association. We can therefore celebrate its 70th anniversary and above all to congratulate WMA for keeping the true wisdom of medical ethics and therefore also the integrity of the medical profession to this day. In any medical decision the best interest of individual patient should be considered first.

El uso de placebo en ensayos clínicos de fase III en Brasil / The use of placebos in phase III clinical trials in Brazil

El Consejo Federal de Medicina de Brasil (CFM) -órgano normativo y fiscalizador del ejercicio ético de la medicina- prohibió, en 2008, la participación de médicos brasileños en investigaciones que utilizaran placebo para enfermedades con tratamiento eficaz y efectivo, en contraposición a la Declaración de Helsinki, que permite su uso en condiciones metodológicamente justificadas. Con el objetivo de verificar si la normativa ética del CFM modificó el uso de placebo en ensayos clínicos de fase III en Brasil, se analizaron varias características de sus registros en el ClinicalTrials.gov, en los períodos de 2003 a 2007 y de 2009 a 2013. Se concluye que: a) la normativa promulgada por el CFM en 2008 fue ineficaz y prevaleció la posición adoptada por la Declaración de Helsinki; b) el patrocinio de ensayos con placebo por parte de la industria farmacéutica multinacional fue significativo; c) predominaron las investigaciones de fármacos para enfermedades crónicas, y fueron poco significativas para las enfermedades postergadas, de importancia para Brasil.

In 2008, Brazil's Federal Council of Medicine [Conselho Federal de Medicina] (CFM) - regulatory and supervisory agency on the ethical practice of medicine - banned the participation of Brazilian doctors in studies using placebos for diseases with efficient and effective treatment. This position differs with the Helsinki Declaration, which allows the use of placebos in methodologically justified conditions. To ascertain whether the CMF's ethical regulation modified the use of placebos in phase III clinical trials in Brazil, characteristics of the records in ClinicalTrials.gov were researched in the periods from 2003 to 2007 and from 2009 to 2013. The conclusions reached were: a) the regulations issued by the CFM in 2008 were ineffective and the position adopted by the Helsinki Declaration prevails; b) there was significant sponsorship by the multinational pharmaceutical industry of trials with placebos; c) the research was predominantly on new drugs for chronic diseases, with little study done of the neglected diseases which are of great importance to Brazil.

El uso de placebo en ensayos clínicos de fase III en Brasil / The use of placebos in phase III clinical trials in Brazil

El Consejo Federal de Medicina de Brasil (CFM) -órgano normativo y fiscalizador del ejercicio ético de la medicina- prohibió, en 2008, la participación de médicos brasileños en investigaciones que utilizaran placebo para enfermedades con tratamiento eficaz y efectivo, en contraposición a la Declaración de Helsinki, que permite su uso en condiciones metodológicamente justificadas. Con el objetivo de verificar si la normativa ética del CFM modificó el uso de placebo en ensayos clínicos de fase III en Brasil, se analizaron varias características de sus registros en el ClinicalTrials.gov, en los períodos de 2003 a 2007 y de 2009 a 2013. Se concluye que: a) la normativa promulgada por el CFM en 2008 fue ineficaz y prevaleció la posición adoptada por la Declaración de Helsinki; b) el patrocinio de ensayos con placebo por parte de la industria farmacéutica multinacional fue significativo; c) predominaron las investigaciones de fármacos para enfermedades crónicas, y fueron poco significativas para las enfermedades postergadas, de importancia para Brasil.(AU)

In 2008, Brazils Federal Council of Medicine [Conselho Federal de Medicina] (CFM) - regulatory and supervisory agency on the ethical practice of medicine - banned the participation of Brazilian doctors in studies using placebos for diseases with efficient and effective treatment. This position differs with the Helsinki Declaration, which allows the use of placebos in methodologically justified conditions. To ascertain whether the CMFs ethical regulation modified the use of placebos in phase III clinical trials in Brazil, characteristics of the records in ClinicalTrials.gov were researched in the periods from 2003 to 2007 and from 2009 to 2013. The conclusions reached were: a) the regulations issued by the CFM in 2008 were ineffective and the position adopted by the Helsinki Declaration prevails; b) there was significant sponsorship by the multinational pharmaceutical industry of trials with placebos; c) the research was predominantly on new drugs for chronic diseases, with little study done of the neglected diseases which are of great importance to Brazil.(AU)

Eticidade do uso de placebo em pesquisa clínica: proposta de algoritmos decisórios / Ethics of the use of placebos in clinical research: a proposal for decision-making algorithms

O uso de placebo em pesquisa clínica tem sido motivo de debate nos últimos anos, sobretudo após a Associação Médica Mundial publicar, em 2002, nota de esclarecimento do parágrafo 29 da Declaração de Helsinki. O Brasil tem se destacado por sua posição firme e contrária ao uso flexível de placebo. Tanto o Conselho Federal de Medicina quanto o Conselho Nacional de Saúde editaram resoluções que normatizam seu uso no Brasil, de forma a não admiti-lo em caso da existência de um método terapêutico melhor. O presente artigo reforça essa posição e tem por objetivo descrever as diversas aplicações de placebo em pesquisa clínica, bem como trazer à luz a complexa decisão sobre a eticidade de seu uso. Além disso, os autores propõem uma reflexão acerca da utilização de placebo no âmbito da pesquisa, por meio de algoritmos decisórios baseados nas normativas éticas brasileiras...

The use of placebos in clinical research has been a matter of considerable debate in recent years, notably when the World Medical Association published, in 2002, a note of clarification for paragraph 29 of the Helsinki Declaration. Brazil is known for its strong opposition to the flexible use of placebos. Both the Federal Council of Medicine and the National Health Council have published resolutions regulating the use of placebos in Brazil, preventing their use if there is a more effective therapeutic method already in place. The present study reinforces that position and aims to describe the various uses of placebos in clinical research, as well as examining the complex decisions relating to the ethics of their use. Additionally, the authors propose a reflection on the use of placebos through decision-making algorithms based on Brazilian ethical standards...

El uso del placebo en la investigación clínica ha sido un tema de debate en los últimos años, sobre todo después de que la Asociación Médica Mundial publicara, en 2002, una nota aclaratoria del párrafo 29 de la Declaración de Helsinki. Brasil se ha destacado por su firme posición en contra de la utilización flexible del placebo. Tanto el Consejo Federal de Medicina como el Consejo Nacional de Salud editaron resoluciones que regulan el uso del placebo en Brasil, no admitiéndose su uso cuando existe un mejor método terapéutico. El presente artículo refuerza esa posición y tiene como objetivo describir diferentes usos del placebo en la investigación clínica, así como contribuir en la discusión sobre la ética de su uso. Además, los autores proponen una reflexión sobre el uso del placebo en la investigación a través de algoritmos para la toma de decisiones, los cuales se basan en las normativas éticas de Brasil...

50th anniversary of the Declaration of Helsinki: the double standard was introduced.

The Declaration of Helsinki (DoH), adopted by the World Medical Association (WMA), is one of the most influential international documents in research ethics, is turning 50 in 2014. Its regular updates, seven versions (1975, 1983, 1989, 1996, 2000, 2008, 2013) and two notes of clarification (2002, 2004), characterize it as a 'live' document. The seventh version of the DoH was amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. The new version was reorganized and restructured, with paragraphs subdivided and regrouped. However, the DoH remains controversial and some ethical issues are still uncovered. The major problem was the insertion of the phrase 'less effective than the best proven' on placebo paragraph in order to allow double standard in medical research in low-resource countries. The DoH is a 'live' document, which will continually have to deal with new topics and challenges. Health equity needs to be a priority, and with that, a single ethical standard for medical research.

Qualidade dos estudos clínicos publicados na RBGO ao longo de uma década (1999-2009): aspectos metodológicos, éticos e procedimentos estatísticos / Quality of clinical studies published in the RBGO over one decade (1999-2009): methodological and ethical aspects and statistical procedures

OBJETIVO: Avaliar a evolução metodológica e do delineamento estatístico nas publicações da Revista Brasileira de Ginecologia e Obstetrícia (RBGO) a partir da resolução 196/96. MÉTODOS: Uma revisão de 133 artigos publicados nos anos de 1999 (65) e 2009 (68) foi realizada por dois revisores independentes com formação em epidemiologia clínica e metodologia da pesquisa científica. Foram incluídos todos os artigos clínicos originais, séries e relatos de casos, sendo excluídos os editoriais, as cartas ao editor, os artigos de revisão sistemática, os trabalhos experimentais, artigos de opinião, além dos resumos de teses e dissertações. Características relacionadas com a qualidade metodológica dos estudos foram analisadas por artigo, por meio de check-list que avaliou dois critérios: aspectos metodológicos e procedimentos estatísticos. Utilizou-se a estatística descritiva e o teste do χ2 para comparação entre os anos. RESULTADOS: Observa-se que houve diferença entre os anos de 1999 e 2009 no tocante ao desenho dos estudos e ao delineamento estatístico, demonstrando maior rigor nos respectivos procedimentos com o uso de testes mais robustos, relativamente, entre os anos de 1999 e 2009. CONCLUSÕES: Na RBGO, observou-se evolução metodológica dos artigos publicados entre os anos de 1999 e 2009 e aprofundamento nas análises estatísticas com o uso de testes mais sofisticados, como o uso mais frequente das análises de regressão e da análise multinível, que são técnicas primordiais na produção do conhecimento e planejamento de intervenções em saúde. Isso pode resultar em menos erros de interpretações.

PURPOSE: To evaluate the methodological and statistical design evolution of the publications in the Brazilian Journal of Gynecology and Obstetrics (RBGO) from resolution 196/96. METHODS: A review of 133 articles published in 1999 (65) and 2009 (68) was performed by two independent reviewers with training in clinical epidemiology and methodology of scientific research. We included all original clinical articles, case and series reports and excluded editorials, letters to the editor, systematic reviews, experimental studies, opinion articles, besides abstracts of theses and dissertations. Characteristics related to the methodological quality of the studies were analyzed in each article using a checklist that evaluated two criteria: methodological aspects and statistical procedures. We used descriptive statistics and the χ2 test for comparison of the two years. RESULTS: There was a difference between 1999 and 2009 regarding the study and statistical design, with more accuracy in the procedures and the use of more robust tests between 1999 and 2009. CONCLUSIONS: In RBGO, we observed an evolution in the methods of published articles and a more in-depth use of the statistical analyses, with more sophisticated tests such as regression and multilevel analyses, which are essential techniques for the knowledge and planning of health interventions, leading to fewer interpretation errors.

Emancipação na luta pela equidade em pesquisas com seres humanos / Emancipation in the struggle for equality in research involving human volunteers

Este artigo apresenta como estudo de caso os aspectos mais controversos de pesquisa conduzida na Guatemala (1946-1948), patrocinada pelo Serviço de Saúde Pública dos Estados Unidos e envolvendo participantes infectados intencionalmente pelo Treponema pallidum. Analisando as alterações de 2008 na Declaração de Helsinque e a ainda pequena adesão a outros instrumentos internacionais, como a Declaração Universal sobre Bioética e Direitos Humanos, da Unesco, a discussão enfatiza a importância da implantação de diretrizes éticas internacionalmente aceitas para impedir que voluntários humanos sejam envolvidos em pesquisas não éticas. Conclui considerando que é indispensável o envolvimento de cientistas e ativistas para alcançar padrões éticos universalmente aceitos e aplicáveis, visando evitar duplo standard. Além disso, que a participação igualitária em pesquisas e distribuição justa de seus benefícios será importante passo para atingir o acesso universal a cuidados de saúde de qualidade para todos.

This manuscript presents as a case study the most controversial aspects of a research conducted in Guatemala(1946-1948), sponsored by the United States Public Health Service in which participants were intentionallyinfected with Treponema pallidum. The analysis of changes in the 2008 Declaration of Helsinki and the stillinsufficient adherence to UNESCO ́s Universal Declaration on Bioethics and Human Rights emphasizes theimportance of applying internationally accepted ethical standards for human volunteers to prevent unethicalresearch. It concludes that the involvement of scientists and activists is crucial to achieve internationally accepted ethical standards to be equally applied throughout the world, avoiding the risks of double standards,and also that egalitarian participation in research and fair distribution of its benefits will be an important steptowards universal access to good quality healthcare for all people.

A nova declaração de Helsinque e o uso de placebo em estudos clínicos no Brasil: a polêmica continua / The new declaration of Helsinki and the use of placebo in brazilian clinical trials: controversy remains

Em 2000, dada a urgência de adequação à realidade científica vigente, iniciativas de revisão dos aspectos polêmicos da Declaração de Helsinque (DoH) à publicação de sua quinta versão na qual ficou estabelecido que o uso do placebo seria aceito apenas quando nenhum tratamento existisse. A Federal Drug Administration nos E.U.A., todavia, continuou a exigir controle-placebo, adotando o Guia de Boas Práticas Clínicas. Também a Agência ReguladoraEuropeia considerou tal proibição arbitrária e, junto a outras entidades, lançaram-se numa campanha contra a DoH. Em 2002 e 2004, Notas de Clarificação publicadas na DoH provocaram grande comoção mundial, culminando na versão de 2008. Apesarda divergência dentre vários grupos, sobretudo, quanto ao uso do placebo, o texto atual assumiu uma posição neutra, flexibilizando sua aplicação. Todavia, uma vez norma ética, a atual DoH fomentou o reinício das discussões sobre a necessidade de um documento mais ampla e uniformemente aceito. Hoje, esta polêmica ainda continua em alguns países, principalmente no Brasil, onde o Conselho Federal de Medicina (CFM) e a Comissão Nacional de Ética em Pesquisa (CONEP) proíbem o uso de placebo em estudos clínicos em território nacional, quando existir qualquer tratamento disponível. Este fato eliciou grande polêmica entre agências regulatórias e pesquisadores brasileiros. Assim, dado que, desde Nuremberg, a garantia do não enfraquecimento das normas de proteção dos sujeitos de pesquisa recrutados mundo afora é razão primordial de ser da DoH, a reabertura de diálogo em níveis nacional einternacional se faz premente perante a nova revisão comemorativa de seus 50 anos em 2014...

In 2000, given the urgency for the ethical guidelines adequacy to the present scientific standards, revision initiatives of the most controversial aspects of the Declaration of Helsinki (DoH). These efforts culminated with the publication of its fifth version stating that the use of placebo was acceptable when proven treatmentdoes not exist. The US Federal Drug Administration, however, continued demanding the placebo control and adopted the Good Clinical Practice Guidelines. The European regulatory agency also considered such prohibition arbitrary and, amongst other entities,started a campaign against the DoH. In 2002 and 2004, Clarification Notes published on the DoH promoted extensive controversy worldwide, concluded at its version of 2008. Despite the divergence amongst many groups, especially on placebo use, the current text assumed a more neutral positioning, flexibilising its application. Being an ethical norm, the current DoH re-started the discussions about thenecessity of a document of uniform worldwide acceptance. Today, the controversy still remains in a few countries, especially in Brazil, where governmental regulatory agencies – namely the Federal Council of Medicine and the National Commission for Research Ethics – posed a ban on the placebo use in clinical trials nationally,when there is available treatment, corroborating with the ongoingcontroversy amongst regulatory agencies and researchers in Brazil.Therefore, since Nuremberg, given the warranty of not weakening the protection of research subjects recruited throughout the worldconstitutes the DoH most desired aim, dialogue must be resumed both nationally and internationally, considering the upcoming revisionin 2014, at the DoH 50th anniversary...

An update on research ethics in Asia / Journal of the ASEAN Federation of Endocrine Societies

There are many international guidelines that have been developed to ensure that the conduct of researches by countries, institutions and individuals are ethical. There are, however, unique opportunities as well as challenges in research in the ASEAN region which mandate not only adherence to these guidelines but which necessitate regional as well as individual country efforts to ensure that biomedical researches uphold the dignity, ensure safety and protect the rights of participants. Some of the challenges are: the widespread poverty or uneven distribution of resources in developing countries which cause patients to participate in clinical trials to avail of services that otherwise are inaccessible, lack of a research infrastructure that makes ethics review of protocols inadequate or slow, and lack of post-trial access to medications which have been tested in precisely the populations that need these drugs. The aim of this paper is to review the ethical challenges in health research encountered in Asia and to describe the regional efforts being undertaken to address them.